AR057745A1 - Formulaciones de disoluciones de hfc que contienen hidrocloruro de salbutamol o citrato de salbutamol - Google Patents

Formulaciones de disoluciones de hfc que contienen hidrocloruro de salbutamol o citrato de salbutamol

Info

Publication number
AR057745A1
AR057745A1 ARP060103518A ARP060103518A AR057745A1 AR 057745 A1 AR057745 A1 AR 057745A1 AR P060103518 A ARP060103518 A AR P060103518A AR P060103518 A ARP060103518 A AR P060103518A AR 057745 A1 AR057745 A1 AR 057745A1
Authority
AR
Argentina
Prior art keywords
salbutamol
formulations
hfc
citrate
hydrochloride
Prior art date
Application number
ARP060103518A
Other languages
English (en)
Inventor
Friedrich Schmidt
Mariola Mann
Michael Cope
Holger Memmesheimer
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR057745A1 publication Critical patent/AR057745A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/56—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups
    • C07C215/58—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
    • C07C215/60—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain the chain having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265—Citric acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Formulaciones de disolucion para aerosol estabilizadas que contienen sales de adicion de ácido de salbutamol, que son adecuadas para su administracion por inhaladores de dosis medida (los MDI). Más en particular, formulaciones de una disolucion que contiene hidrocloruro de salbutamol o citrato de salbutamol, una de las dos sales mencionadas anteriormente en combinacion con una o más sustancias farmacologicamente activas adicionales, junto con un hidrofluorocarbono (HFC) medioambientalmente seguro como propelente, un disolvente conjunto, y un ácido inorgánico o un ácido orgánico.
ARP060103518A 2005-08-12 2006-08-11 Formulaciones de disoluciones de hfc que contienen hidrocloruro de salbutamol o citrato de salbutamol AR057745A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05017599 2005-08-12

Publications (1)

Publication Number Publication Date
AR057745A1 true AR057745A1 (es) 2007-12-12

Family

ID=35564491

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103518A AR057745A1 (es) 2005-08-12 2006-08-11 Formulaciones de disoluciones de hfc que contienen hidrocloruro de salbutamol o citrato de salbutamol

Country Status (6)

Country Link
US (1) US20070041911A1 (es)
AR (1) AR057745A1 (es)
PE (1) PE20070353A1 (es)
TW (1) TW200800141A (es)
UY (1) UY29740A1 (es)
WO (1) WO2007020204A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0501956D0 (en) * 2005-01-31 2005-03-09 Arrow Internat Nebulizer formulation
GB201108039D0 (en) 2011-05-13 2011-06-29 Mexichem Amanco Holding Sa Compositions
GB201117621D0 (en) 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
GB201117619D0 (en) 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
GB201306984D0 (en) 2013-04-17 2013-05-29 Mexichem Amanco Holding Sa Composition
BR122020022602B1 (pt) 2015-12-04 2024-03-05 Mexichem Fluor S.A. De C.V. Composição farmacêutica
CA3037107C (en) 2016-09-19 2021-05-18 Mexichem Fluor S.A. De C.V. Stable pharmaceutical compositions comprising salmeterol and 1,1-difluoroethane (hfa-152a) suitable for use in metered dose inhalers (mdis)
BR112019005080A2 (pt) 2016-09-19 2019-06-04 Mexichem Fluor Sa De Cv composição farmacêutica, recipiente vedado, inalador de dose medida, e, métodos para tratar um paciente sofrendo ou susceptível de sofrer de um distúrbio respiratório, para melhorar a estabilidade de uma composição farmacêutica, para aumentar o tempo de estabilização de uma composição farmacêutica, para melhorar o desempenho de aerossolização de uma composição farmacêutica e para reduzir o potencial de aquecimento global de uma composição farmacêutica.
AU2017328907B2 (en) 2016-09-19 2020-04-09 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
MA52756A (fr) * 2018-06-04 2021-04-14 Lupin Inc Compositions pharmaceutiques stables pour inhalateurs doseurs sous pression
FR3130554A1 (fr) * 2021-12-20 2023-06-23 Aptar France Sas Composition pharmaceutique comprenant du salbutamol

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8828477D0 (en) * 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
DE69232818T2 (de) * 1991-06-10 2003-06-18 Schering Corp., Kenilworth Fluorchlorkohlenwasserstofffreie Aerosolformulierungen
JP2003221335A (ja) * 2001-10-26 2003-08-05 Dey Lp 慢性閉塞性肺疾患の症状を緩和するためのアルブテロールおよびイプラトロピウム吸入溶液、システム、キットおよび方法
CN1216600C (zh) * 2002-04-24 2005-08-31 信谊药厂 盐酸左旋沙丁胺醇气雾剂及制备工艺
CN1228045C (zh) * 2003-11-03 2005-11-23 王立强 口腔速崩速溶片制剂及其制备方法
GB0406069D0 (en) * 2004-03-17 2004-04-21 Thompson James Process

Also Published As

Publication number Publication date
WO2007020204A2 (en) 2007-02-22
PE20070353A1 (es) 2007-04-19
TW200800141A (en) 2008-01-01
UY29740A1 (es) 2007-03-30
WO2007020204A3 (en) 2007-06-07
US20070041911A1 (en) 2007-02-22

Similar Documents

Publication Publication Date Title
AR057745A1 (es) Formulaciones de disoluciones de hfc que contienen hidrocloruro de salbutamol o citrato de salbutamol
AR059350A1 (es) Formulacion farmaceutica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva
UY29562A1 (es) Compuestos heterocíclicos de amino benzoilo, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
AR067309A1 (es) Formulaciones farmaceuticas que contienen derivados de acido lipoico
AR057180A1 (es) Formulacion farmaceutica de absorcion oral que comprende insulina, entre otros, y su metodo de administracion
AR059359A1 (es) Formulaciones farmaceuticas que contienen pleconaril
UY30759A1 (es) Compuestos quimicos
CY1115150T1 (el) Βοηθηματα διαλυτοποιησης για τη χορηγηση πεπτιδιων απο το στομα, τα οποια περιεχουν διγουανιδη
EP1894567A4 (en) PHARMACEUTICAL COMPANION THERAPIES AND THEIR USE
CL2008000442A1 (es) Composicion farmaceutica que comprende a un quitosano, un ingrediente activo cosmetico o farmaceutico, y un solvente volatil; y su uso para tratar psoriasis, micosis entre otras enfermedades.
CR8947A (es) Metodo de montaje de dispositivos para la administracion de farmacos
DK1257254T3 (da) Formuleringer indeholdende et anticholinergt lægemiddel til behandling af kronisk obstruktiv lungesygdom
MA28921B1 (fr) Derive heterocyclique azote et medicament le contenant en tant que principe actif
BRPI0507225A2 (pt) formulações estáveis de solução farmacêutica para inaladores pressurizados de dose medida
NO20080220L (no) Formuleringer med hoy medikament belastning og doseringsformer
NI201500163A (es) Composiciones, métodos y sistemas para el suministro por vía respiratoria de tres o más agentes activos.
UY33201A (es) Compuestos de pirazol como antagonistas de crth2.
NO20082097L (no) Farmasoytiske sammensetninger
CO6351721A2 (es) Uso de dronedarona para la preparacion de un medicamento para la prevencion de ictus o ataque isquemico transitorio
AR060303A1 (es) Formulaciones farmaceuticas sales de 8- [1- (3,5 -bis- (trifluorometil) fenil) -etoximetil] -8-fenil-1,7 -diaza-espiro [4.5] decan -2- ona y metodos de tratamiento utilizando las mismas
NO20074854L (no) Farmasoytiske aerosolformuleringer for komprimerte, utmalte doseinhalatorer omfattende et sekvestreringsmiddel
DK2089008T3 (da) Formulationer til afgivelse via tryksatte, afmålte dosisinhalatorer omfattende en essentiel olie som suspensionsstabilisator
WO2007009691A3 (en) Combination of substituted pyrazolines and anti -addictive agent
NO20083759L (no) Doserings aerosoler for administrering av farmasoytiske preparater
UY29561A1 (es) Derivados de quinazolina, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones

Legal Events

Date Code Title Description
FA Abandonment or withdrawal